Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2018, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.
Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 10, 60 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.
Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Traumatic Brain Injury - Pipeline Review, H1 2018
Table of Contents
Table of Contents 2
Introduction 5
Traumatic Brain Injury - Overview 6
Traumatic Brain Injury - Therapeutics Development 7
Traumatic Brain Injury - Therapeutics Assessment 20
Traumatic Brain Injury - Companies Involved in Therapeutics Development 32
Traumatic Brain Injury - Drug Profiles 49
Traumatic Brain Injury - Dormant Projects 243
Traumatic Brain Injury - Discontinued Products 247
Traumatic Brain Injury - Product Development Milestones 248
Appendix 260
List of Tables
Number of Products under Development for Traumatic Brain Injury, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2018
Traumatic Brain Injury - Pipeline by Aptinyx Inc, H1 2018
Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2018
Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2018
Traumatic Brain Injury - Pipeline by CalciMedica Inc, H1 2018
Traumatic Brain Injury - Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2018
Traumatic Brain Injury - Pipeline by Complement Pharma BV, H1 2018
Traumatic Brain Injury - Pipeline by Eisai Co Ltd, H1 2018
Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2018
Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2018
Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2018
Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2018
Traumatic Brain Injury - Pipeline by JT Pharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2018
Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018
Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2018
Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2018
Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2018
Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2018
Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2018
Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2018
Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2018
Traumatic Brain Injury - Pipeline by NoNO Inc, H1 2018
Traumatic Brain Injury - Pipeline by Noxopharm Ltd, H1 2018
Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2018
Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2018
Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2018
Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by Rubicon Biotechnology Inc, H1 2018
Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2018
Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2018
Traumatic Brain Injury - Pipeline by Scythian Biosciences Corp, H1 2018
Traumatic Brain Injury - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2018
Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2018
Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2018
Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2018
Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2018
Traumatic Brain Injury - Pipeline by Therapix Biosciences Ltd, H1 2018
Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2018
Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2018
Traumatic Brain Injury - Dormant Projects, H1 2018
Traumatic Brain Injury - Dormant Projects, H1 2018 (Contd..1), H1 2018
Traumatic Brain Injury - Dormant Projects, H1 2018 (Contd..2), H1 2018
Traumatic Brain Injury - Dormant Projects, H1 2018 (Contd..3), H1 2018
Traumatic Brain Injury - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Traumatic Brain Injury, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Global Restless Legs Syndrome Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 112
According to our LPI (LP Information) latest study, the global Restless Legs Syndrome market size was valued at US$ million in 2023. With growing demand in downstream market, the Restless Legs Syndrome is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Restless Legs Syndrome market. Restless Legs Syndrome are expected to show stable growth in the future market. However, product di......
Global Autism Spectrum Disorder Market Research Report 2024 (Status and Outlook)
Published: 15-Dec-2023 Price: US 3200 Onwards Pages: 110
Report Overview:
Autism spectrum disorder is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests and activities. Diagnosing autism spectrum disorder (ASD) can be difficult, since there is no medical test, like a blood test, to diagnose the disorders. Doctors look at the child's behavior and development to make a diagnosis. Our report studies the market......
Global Epilepsy Therapeutics Market Research Report 2023
Published: 14-Dec-2023 Price: US 2900 Onwards Pages: 86
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Epilepsy Therapeutics market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Abbott Laboratories
- Cephalon
- Novartis
- Pfizer
- Johnson & Johnson
- GlaxoSmithKline
- Sanofi
- Sunovion Pharmaceuticals......
Global Autism Spectrum Disorder Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 30-Nov-2023 Price: US 3380 Onwards Pages: 109
Market Overview of Global Autism Spectrum Disorder market:
According to our latest research, the global Autism Spectrum Disorder market looks promising in the next 5 years. As of 2022, the global Autism Spectrum Disorder market was estimated at USD 464.19 million, and it's anticipated to reach USD 700.88 million in 2028, with a CAGR of 7.11% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of ......
Global Autism Spectrum Disorder Market Status and Outlook 2023-2028
Published: 24-Nov-2023 Price: US 3160 Onwards Pages: 109
Autism spectrum disorder (ASD) is a complex developmental condition that involves persistent challenges in social interaction, speech and nonverbal communication, and restricted/repetitive behaviors. The effects of ASD and the severity of symptoms are different in each person.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segmen......
Global Epilepsy Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 16-Nov-2023 Price: US 3380 Onwards Pages: 112
Market Overview of Global Epilepsy Therapeutics market:
According to our latest research, the global Epilepsy Therapeutics market looks promising in the next 5 years. As of 2022, the global Epilepsy Therapeutics market was estimated at USD 11157.84 million, and it's anticipated to reach USD 13510.46 million in 2028, with a CAGR of 3.24% during the forecast years.
Epilepsy is a group of neurological disorders characterized by seizures. The onset of a seizure can range from a b......
Global Gabapentin Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 12-Oct-2023 Price: US 3380 Onwards Pages: 98
Market Overview of Global Gabapentin market:
According to our latest research, the global Gabapentin market looks promising in the next 5 years. As of 2022, the global Gabapentin market was estimated at USD 1627.13 million, and it's anticipated to reach USD 1844.92 million in 2028, with a CAGR of 2.12% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Gabapentin market, with a sys......
2023-2031 Report on Global Autism Spectrum Disorder Market by Player, Region, Type, Application and Sales Channel
Published: 09-Oct-2023 Price: US 2500 Onwards Pages: 89
This report studies the Autism Spectrum Disorder market, covering market size for segment by type (Center-Based, In-Home, etc.), by application (1-14 Years Old, 15-25 Years Old, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Otsuka, Astrazeneca, Pfizer, Eli Lilly, Johnson & Johnson, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa).
This report provides detailed historical analysis of global market for Aut......
Global Gabapentin Market Insights, Forecast to 2029
Published: 27-Sep-2023 Price: US 4900 Onwards Pages: 112
Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
The global Gabapentin market is projected to grow from US$ 1572.1 million in 2023 to US$ 1749.7 million by 2029, at a Compound Annual Growth Ra......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
